Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

NCT04578756 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Bipolar I Disorder
Autism Spectrum Disorder (ASD)

Interventions

DRUG: Cariprazine Flexible Dose
DRUG: Cariprazine Flexible Dose

Sponsor

AbbVie